{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:02:33Z","timestamp":1790960553934,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jaad.2023.11.005","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T01:58:20Z","timestamp":1699581500000},"page":"494-503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)"],"prefix":"10.1016","volume":"90","author":[{"given":"Richard B.","family":"Warren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars E.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mrowietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish J.A.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Soerensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten O.A.","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim D.","family":"Kj\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10281","key":"10.1016\/j.jaad.2023.11.005_bib1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jaad.2023.11.005_bib2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/jdv.18812","article-title":"Oral orismilast: efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets","volume":"37","author":"Warren","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2023.11.005_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3892\/etm.2021.11102","article-title":"Metabolic comorbidities of psoriasis (Review)","volume":"23","author":"Branisteanu","year":"2022","journal-title":"Exp Ther Med"},{"issue":"11","key":"10.1016\/j.jaad.2023.11.005_bib4","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3390\/biomedicines9111511","article-title":"Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches","volume":"9","author":"Campanati","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaad.2023.11.005_bib5","first-page":"21","article-title":"Phosphodiesterase-4 inhibition in psoriasis","volume":"11","author":"Milakovic","year":"2021","journal-title":"Psoriasis (Auckl)"},{"issue":"5","key":"10.1016\/j.jaad.2023.11.005_bib6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey","volume":"70","author":"Lebwohl","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.11.005_bib7","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.11.005_bib8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.11.005_bib10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13555-021-00635-4","article-title":"Evolution of patient perceptions of psoriatic disease: results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey","volume":"12","author":"Lebwohl","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2023.11.005_bib11","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2147\/PPA.S242336","article-title":"Treatment mode preferences in psoriatic arthritis: a qualitative multi-country study","volume":"14","author":"Aletaha","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"10.1016\/j.jaad.2023.11.005_bib12","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/1346-8138.16746","article-title":"A discrete choice experiment on oral and injection treatment preferences among moderate-to-severe psoriasis patients in Japan","volume":"50","author":"Komine","year":"2023","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.11.005_bib13","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/bjd.15756","article-title":"Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice","volume":"177","author":"Cohen","year":"2017","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2023.11.005_bib14","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.11.005_bib15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine kinase 2 and Janus kinase\u2012signal transducer and activator of transcription signaling and inhibition in plaque psoriasis","volume":"86","author":"Krueger","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.11.005_bib16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/jdv.18818","article-title":"Pharmacology of orismilast, a potent and selective PDE4 inhibitor","volume":"37","author":"Silverberg","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2023.11.005_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"20","key":"10.1016\/j.jaad.2023.11.005_bib19","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2023.11.005_bib20","unstructured":"European Medicines Agency. Guideline for good clinical practice E6(R2). 2016. Accessed March 2023. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-good-clinical-practice-e6r2-step-5_en.pdf"},{"key":"10.1016\/j.jaad.2023.11.005_bib21","unstructured":"US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 5, 2017. Accessed May 2023. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"issue":"3","key":"10.1016\/j.jaad.2023.11.005_bib22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)","volume":"31","author":"Reich","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2023.11.005_bib23","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.11.005_bib25","article-title":"Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis\u2014a randomized controlled trial (PSORRO)","volume":"30","author":"Gyldenl\u00f8ve","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"12","key":"10.1016\/j.jaad.2023.11.005_bib26","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1001\/jamadermatol.2022.3862","article-title":"Association of apremilast with vascular inflammation and cardiometabolic function in patients with psoriasis: the VIP-A phase 4, open-label, nonrandomized clinical trial","volume":"158","author":"Gelfand","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2023.11.005_bib27","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1016\/j.cgh.2019.12.032","article-title":"Effects of apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis","volume":"18","author":"Danese","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.11.005_bib28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/jdv.15354","article-title":"Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers","volume":"33","author":"Vossen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223031870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223031870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:30:43Z","timestamp":1759275043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223031870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0190962223031870"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.11.005","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}